| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Prospects for the development of novel anti-hyperlipidemic drugs. | Curr Opin Investig Drugs | 2006 | 1.27 |
| 2 | Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. | J Am Soc Hypertens | 2013 | 0.86 |
| 3 | Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. | Intern Med | 2007 | 0.81 |
| 4 | Pioglitazone is a valid alternative to rosiglitazone. | Am J Cardiovasc Drugs | 2011 | 0.78 |